Patients with acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) have historically poor outcomes with conventional chemotherapy regimens.
Davis Phillips, MD, internal medicine resident, and Josh Zeidner, MD, associate professor of medicine in the division of hematology, published an article that reviews the data for existing therapeutic options for patients with AML-MRC and the emerging therapies undergoing clinical trial development for this patient population. The authors conclude that clinical trials focused specifically on this patient population are urgently needed.
Read the article published in Expert Opinion on Emerging Drugs.